Literature DB >> 19591128

Effect of hepatitis C virus and its treatment on survival.

Adeel A Butt1, Xiaoqiang Wang, Charity G Moore.   

Abstract

UNLABELLED: The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV-infected veterans and uninfected controls. We used a national sample of HCV-infected persons and HCV-uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV-infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan-Meier survival plots were generated to determine and compare survival among HCV-infected and HCV-uninfected persons, and among treated and untreated HCV-infected persons.We identified 34,480 matched pairs of HCV-infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31-1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV-infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27-0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0-23 weeks and 24-47 weeks of treatment, respectively) compared with untreated subjects.
CONCLUSION: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591128     DOI: 10.1002/hep.23000

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

1.  Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease.

Authors:  Adeel A Butt; Chung-Chou Chang; Lewis Kuller; Matthew Bidwell Goetz; David Leaf; David Rimland; Cynthia L Gibert; Krisann K Oursler; Maria C Rodriguez-Barradas; Joseph Lim; Lewis E Kazis; Stephen Gottlieb; Amy C Justice; Matthew S Freiberg
Journal:  Arch Intern Med       Date:  2011-04-25

2.  Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.

Authors:  Myrna L Cozen; James C Ryan; Hui Shen; Ramsey Cheung; David E Kaplan; Christine Pocha; Norbert Brau; Ayse Aytaman; Warren N Schmidt; Marcos Pedrosa; Bhupinderjit S Anand; Kyong-Mi Chang; Timothy Morgan; Alexander Monto
Journal:  Dig Dis Sci       Date:  2016-04-08       Impact factor: 3.199

3.  Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US.

Authors:  Ramsey Cheung; Ajitha Mannalithara; Gurkirpal Singh
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

4.  Hepatitis C treatment completion rates in routine clinical care.

Authors:  Adeel A Butt; Kathleen A McGinnis; Melissa Skanderson; Amy C Justice
Journal:  Liver Int       Date:  2009-11-04       Impact factor: 5.828

5.  Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.

Authors:  Alexis P Chidi; Cindy L Bryce; Julie M Donohue; Michael J Fine; Douglas P Landsittel; Larissa Myaskovsky; Shari S Rogal; Galen E Switzer; Allan Tsung; Kenneth J Smith
Journal:  Value Health       Date:  2016-03-24       Impact factor: 5.725

6.  Hepatitis C screening: getting it right.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2012-12-24       Impact factor: 17.425

7.  Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.

Authors:  A A Butt; P Yan; O S Shaikh; M S Freiberg; V Lo Re; A C Justice; K E Sherman
Journal:  J Viral Hepat       Date:  2014-12-18       Impact factor: 3.728

8.  The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.

Authors:  A A Butt; T Umbleja; J W Andersen; R T Chung; K E Sherman
Journal:  Aliment Pharmacol Ther       Date:  2011-03-29       Impact factor: 8.171

9.  Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Authors:  Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

10.  Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response.

Authors:  Eric Chak; Sammy Saab
Journal:  Curr Hepat Rep       Date:  2010-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.